Sector
PharmaceuticalsOpen
₹1,990.25Prev. Close
₹1,990.6Turnover(Lac.)
₹764.29Day's High
₹2,009Day's Low
₹1,961.152 Week's High
₹2,19452 Week's Low
₹1,190Book Value
₹546.07Face Value
₹1Mkt Cap (₹ Cr.)
32,974.23P/E
31.46EPS
63.33Divi. Yield
07 Jun 2024
12:00 AM
Board Meeting
Agenda : Audited Result
18 May 2023
12:00 AM
AGM
Announcement Date: 18 May, 2023
| Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|
Equity Capital | 16.47 | 16.51 | 16.36 | 15.5 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 7,936.83 | 7,141.72 | 5,886.93 | 3,630.74 |
Net Worth | 7,953.3 | 7,158.23 | 5,903.29 | 3,646.24 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2017 |
|---|---|---|---|
Revenue | 4,400.7 | 3,462.87 | 1,479.17 |
yoy growth (%) | 27.08 | 134.1 | |
Raw materials | -2,109.21 | -1,491.87 | -509.73 |
As % of sales | 47.92 | 43.08 | 34.46 |
Employee costs | -338.56 | -311.36 | -153.41 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2017 |
|---|---|---|---|
Profit before tax | 1,619.04 | 1,334.85 | 578.01 |
Depreciation | -110.29 | -98.78 | -74.14 |
Tax paid | -406.88 | -337.84 | -164.28 |
Working capital | 496.99 | 3,455.68 | |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2017 |
|---|---|---|---|
Growth matrix (%) | |||
Revenue growth | 27.08 | 134.1 | |
Op profit growth | 16 | 108.36 | |
EBIT growth | 21.37 | 128.99 | |
Net profit growth | 21.57 | 140.98 |
| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|---|
Gross Sales | 5,664.72 | 3,624.6 | 4,400.71 | 3,462.88 | 2,633.24 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 5,664.72 | 3,624.6 | 4,400.71 | 3,462.88 | 2,633.24 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 170.24 | 240.46 | 223.94 | 134.78 | 139.17 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,568.65 | 123.31 | 3,76,323.69 | 867.6 | 0.86 | 5,536.99 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,519.8 | 76.17 | 1,19,994.45 | 531 | 0.66 | 2,259 | 507.93 |
Cipla Ltd CIPLA | 1,485.5 | 32.29 | 1,19,928.54 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,144.45 | 33.51 | 1,15,173.54 | 1,405.2 | 0.26 | 3,172.6 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,636 | 25.85 | 1,10,759.07 | 1,034.8 | 0.6 | 5,081.8 | 1,458.96 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Independent Directo
Yiu Kwan Stanley Lau
Executive Chairman & CEO
SRINIVAS SADU
Non-Exec & Non-Independent Dir
QIYU CHEN
Non-Exec & Non-Independent Dir
UDO JAHANNES VETTER
Independent Director
C S N Murthy
Independent Director
ESSAJI GOOLAM VAHANVATI
Independent Director
Naina Lal Kidwai
Non-Exec & Non-Independent Dir
Jia Ai (Allen) Zhang
Non-Exec & Non-Independent Dir
Yao Fang
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Gland Pharma Ltd
Summary
Gland Pharma Ltd was incorporated as Gland Pharma Private Limited, a private limited company under the Companies Act, 1956 on March 20, 1978 and was granted the certificate of incorporation by Registrar of Companies, Andhra Pradesh at Hyderabad. Subsequently, the name of the Company was changed to Gland Pharma Limited pursuant to a special resolution passed by the shareholders of the Company on December 5, 1994 and a fresh certificate of incorporation dated April 25, 1995 was issued by the Registrar of Companies, Andhra Pradesh at Hyderabad consequent upon change of name and conversion into a public limited company under the Companies Act, 1956. The Company is primarily engaged in manufacturing injectable formulations.The company is one of the fastest growing generic injectables-focused companies by revenue in the United States from 2014 to 2019. The company has 8 manufacturing facilities in India, comprising four finished formulations facilities with a total of 23 production lines and three API facilities. The company sells products primarily under a business to business (B2B) model in over 60 countries as of March 31, 2022, including the United States, Europe, Canada, Australia, India and the Rest of the world. The company has a consistent compliance track record with a range of regulatory regimes across these markets. The company also have an extensive track record in complex injectables development, manufacturing and marketing and a close understanding of the related soph
Read More
What is the Gland Pharma Ltd share price today?
The Gland Pharma Ltd shares price on N/A is Rs.₹1997.75 today.
What is the Market Cap of Gland Pharma Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Gland Pharma Ltd is ₹32913.28 Cr. as of 22 Jul ‘24
What is the PE and PB ratio of Gland Pharma Ltd?
The PE and PB ratios of Gland Pharma Ltd is 31.46 and 3.65 as of 22 Jul ‘24
What is the 52 Week High and Low of Gland Pharma Ltd?
The 52-week high/low is the highest and lowest price at which a Gland Pharma Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Gland Pharma Ltd is ₹1172.05 and ₹2195.75 as of 22 Jul ‘24
What is the CAGR of Gland Pharma Ltd?
Gland Pharma Ltd's CAGR for 5 Years at 1.82%, 3 Years at -19.78%, 1 Year at 67.31%, 6 Month at 1.40%, 3 Month at 13.09% and 1 Month at 9.07%.
What is the shareholding pattern of Gland Pharma Ltd?
The shareholding pattern of Gland Pharma Ltd is as follows:
Promoters - 51.83 %
Institutions - 39.71 %
Public - 8.45 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
